Lilly sells Zepbound vials from $299/mo: compare 11 direct-pay programs →
Affiliate disclosure: we earn commission from some partners. Learn more.

Mounjaro in California (2026)

tirzepatide · GLP-1 weight management · California

Reviewed by the WeighedHealth Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of July 2026; updated when guidance or availability changes.
Last verified by WeighedHealth Editorial Team against primary sources

About Mounjaro

FDA-approved tirzepatide for type 2 diabetes. Off-label for weight loss is common.

See the full Mounjaro review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.

Insurance coverage for Mounjaro in California

Since January 1, 2026, Medi-Cal Rx no longer covers Wegovy, Zepbound, or Saxenda for weight loss for members 21 and older. Prior authorization is reviewed case by case for Wegovy to treat MASH or reduce cardiovascular risk, and for Zepbound to treat obstructive sleep apnea. Members under 21 can still be reviewed under EPSDT. GLP-1s for type 2 diabetes remain covered.

CarrierMounjaro statusDetail
AetnaCoveredMounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Aetna coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card.
Blue Cross Blue ShieldCovered (prior auth required)Blue Cross Blue Shield of Massachusetts continues to cover Mounjaro for type 2 diabetes with prior authorization that includes a documented diabetes diagnosis, after ending weight-loss GLP-1 coverage in 2026. Other Blue plans set their own rules.
UnitedHealthcareCoveredMounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public UnitedHealthcare coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card.
CignaCoveredMounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Cigna coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card.
HumanaCoveredMedicare Part D, including Humana drug plans, covers Mounjaro for type 2 diabetes. Check Humana's formulary for your plan's tier and prior authorization rules.
Kaiser PermanenteCoveredMounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Kaiser Permanente coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card.
AnthemCoveredMounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Anthem commercial coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card.
MedicareCoveredPart D plans cover Mounjaro for type 2 diabetes; tier and prior authorization depend on your plan's formulary. People with type 2 diabetes get GLP-1s through their Part D plan and cannot use the Medicare GLP-1 Bridge.
MedicaidCoveredMassHealth lists Mounjaro as a preferred GIP/GLP-1 drug for diabetes, and California Medi-Cal keeps Mounjaro on its drug list restricted to type 2 diabetes. Neither covers it for weight loss.
TRICARECovered (prior auth required)TRICARE covers Mounjaro for type 2 diabetes for all beneficiaries with prior authorization, plus a medical necessity form for the formulary copayment and for coverage at a military pharmacy.

Telehealth and prescribing in California

A telehealth clinician must be licensed in California to prescribe Mounjaro to you while you are in California.

Platforms differ in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons.

Compounded tirzepatide

On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

Mounjaro in California: common questions

Is Mounjaro legal in California?+

Yes. Mounjaro (tirzepatide) is FDA-approved and legal in all 50 US states including California. State-level differences appear in Medicaid coverage and clinician licensing, not in the legality of the medication itself.

Can I get Mounjaro via telehealth in California?+

Yes, from a clinician licensed in California. A telehealth clinician must be licensed in California to prescribe Mounjaro to you while you are in California.

Does California Medicaid cover Mounjaro?+

Not covered for weight loss. Since January 1, 2026, Medi-Cal Rx no longer covers Wegovy, Zepbound, or Saxenda for weight loss for members 21 and older. Prior authorization is reviewed case by case for Wegovy to treat MASH or reduce cardiovascular risk, and for Zepbound to treat obstructive sleep apnea. Members under 21 can still be reviewed under EPSDT. GLP-1s for type 2 diabetes remain covered.

What's the cheapest way to get Mounjaro in California?+

The main paths are insurance with prior authorization if your plan covers it, manufacturer cash-pay programs, or telehealth programs that include the medication. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.

Is compounded Mounjaro still available in California?+

Compounding rules are federal, not set by California. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

Related